Press Release: uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B

Full Patient Enrollment in Study Expected by Year-End 2019 LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for…

Continue Reading Press Release: uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B
Clinical Trial Results Look Good for Possible Treatment for Transfusion Dependent Beta Thalassemia
sabinurce / Pixabay

Clinical Trial Results Look Good for Possible Treatment for Transfusion Dependent Beta Thalassemia

According to a story from Market Screener, the biopharmaceutical company Orchard Therapeutics recently announced that the results of a recent clinical trial testing the company' investigational product OTL-300 were encouraging.…

Continue Reading Clinical Trial Results Look Good for Possible Treatment for Transfusion Dependent Beta Thalassemia

Parliamentary Debate Highlights Continued Controversy and Misinformation Surrounding CFS/ME

According to a story from The ME Association, a recent debate that came to the floor of the UK parliament highlights the misinformation and deficits in care surrounding children with…

Continue Reading Parliamentary Debate Highlights Continued Controversy and Misinformation Surrounding CFS/ME

Analysis of Phase 3 Study Shows Inolimomab has Long-term Clinical Benefit for Graft-Versus-Host-Disease

About Graft-Versus-Host-Disease (GvHD) Graft-Versus-Host-Disease (GvHD) occurs when a patient's body rejects cells which have been transplanted. For instance, it may develop following a stem cell transplant or a bone marrow transplant. The…

Continue Reading Analysis of Phase 3 Study Shows Inolimomab has Long-term Clinical Benefit for Graft-Versus-Host-Disease
FDA Accepts IND Application for Idiopathic Pulmonary Fibrosis Drug
rawpixel / Pixabay

FDA Accepts IND Application for Idiopathic Pulmonary Fibrosis Drug

According to a press release from X-Rx Inc., a privately-held American biotechnology company, the Food and Drug Administration has accepted the company's Investigational New Drug (IND) application for X-165, an…

Continue Reading FDA Accepts IND Application for Idiopathic Pulmonary Fibrosis Drug

HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy is on Track to Resume

What is Duchenne Muscular Dystrophy? Duchenne muscular dystrophy (DMD) is a rare genetic condition that is ultimately fatal. It causes muscles to weaken and usually results in heart failure before age…

Continue Reading HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy is on Track to Resume
Close Menu